Helmerich & Payne Inc. Common Stock vs 22nd Century Group Inc — how do they compare? Helmerich & Payne Inc. Common Stock trades at $38.25 (market cap $3.91B), while 22nd Century Group Inc trades at $0.65 (market cap $475.95K). The key difference: Helmerich & Payne Inc. Common Stock is far larger — about 8215.1× 22nd Century Group Inc's market cap, and Helmerich & Payne Inc. Common Stock pays a 2.56% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Helmerich & Payne Inc. Common Stock for 0 Days and 22nd Century Group Inc for 33 Days on average.
| HP | XXII | |
|---|---|---|
Market Cap | $3.91B | $475.95K |
Volume | 800,382 | 78,911 |
Sector | Energy | Consumer Staples |
52-Week High | $47.64 | $483.00 |
52-Week Low | $23.11 | $0.65 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $5.54B | -$3.83M |
Dividend Yield | 2.56% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.67, down 7.98% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.06 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives in France and Europe.
Despite analyst optimism (75% buy ratings with $1,240 price target), fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces significant execution risk in commercializing reduced-nicotine tobacco products while navigating regulatory timelines.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Helmerich & Payne, Inc. is a US drilling contractor that designs, builds, and operates high-performance land and offshore drilling rigs for oil and gas producers worldwide.
Read more on HP →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →